Premium
Drug Eluting Stents for Very Long Lesions: Go Long, But Know the Risks
Author(s) -
Beale Charles E.,
Dawn Abbott J.
Publication year - 2017
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27073
Subject(s) - medicine , drug , drug eluting stent , stent , cardiology , radiology , surgery , restenosis , pharmacology
Key Points Long coronary artery lesions are increasingly treated with new technologies including current generation drug eluting stents (DES) despite a lack of robust data on outcomes. In the current study, patients receiving Xience V DES for very long lesions (>35 mm) compared to lesions 25–35 mm had similar outcomes. Future research should address late outcomes, stent thrombosis rates, as well as investigation of lesions greater than 60 mm.